Information Provided By:
Fly News Breaks for May 22, 2017
PBYI
May 22, 2017 | 12:47 EDT
After having a chance to initially review the briefing documents for the FDA advisory committee meeting scheduled to review neratinib for the extended adjuvant treatment of HER2-positive early stage breast cancer, Stifel analyst Thomas Shrader came away with the impression that ExteNet is viewed as "a positive trial in the eyes of the FDA." Noting that "most to all" of the benefit of the drug is in HR+ women, he expects approval for HR+, which he sees as a nice "targeted" population and a "renewed chance to sell the company." Shrader keeps a Buy rating and $88 price target on Puma shares.
News For PBYI From the Last 2 Days
There are no results for your query PBYI
I agree to the thefly.com's disclaimer & terms of use
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.